Atezolizumab induced new-onset type 1 diabetes mellitus.
Joaquín de CarlosLucia ZabalzaJavier GarciaMiguel MartiXabier Ayarza-MarienJon YoldiPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)
T1D related to ICI is a rare condition that presents as a life-threatening emergency and should be recognized and treated early. Blood glucose and glycated hemoglobin determinations should be performed at periodic visits for detection. There are genetic factors that predispose susceptible individuals, but there is no evidence of studies to be performed before the onset of ICI or preventive strategies.
Keyphrases
- blood glucose
- glycemic control
- type diabetes
- high glucose
- emergency department
- public health
- diabetic rats
- blood pressure
- drug induced
- genome wide
- loop mediated isothermal amplification
- case control
- metabolic syndrome
- weight loss
- real time pcr
- label free
- oxidative stress
- insulin resistance
- cardiovascular risk factors
- skeletal muscle
- cardiovascular disease
- newly diagnosed
- sensitive detection